A Randomized, Double Blind Phase III Study of Pembrolizumab vs Placebo in Combination with NeoAdjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High Risk Early Stage Hormone Positive, HER2 Negative Breast Cancer (MK3475-756)
A Randomized, Double Blind Phase III Study of Pembrolizumab vs Placebo in Combination with NeoAdjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High Risk Early Stage Hormone Positive, HER2 Negative Breast Cancer (MK3475-756)
Trial Category:
Breast
Phase
III
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
